Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

P Emery,D E Furst,V P Bykerk,X Mariette,C Arendt,C O Bingham,D Tatla,I Mountian,B Vanlunen,D Van Der Heijde,G R Burmester,O Purcaru,M E Weinblatt,R Van Vollenhoven

doi:10.1136/annrheumdis-2015-209057

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

P Emery, D E Furst + Show 12 more

Open Access

https://doi.org/10.1136/annrheumdis-2015-209057

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: May 10, 2016
Citations: 82	License type: open-access

Affiliation: Hôpitaux Universitaires Paris-Ouest, University of Paris-Sud, Assistance Publique – Hôpitaux de Paris, Institut Polytechnique de Paris, UCB Pharma (Belgium), NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds Teaching Hospitals NHS Trust, UCB Pharma (United States)

#Mean Change From Baseline #Change From Baseline + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesTo assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naïve patients with moderate-to-severe, active, progressive rheumatoid...

Full Text